research Interleukin-10-deficient Mice Are Less Susceptible to the Induction of Alopecia Areata
IL-10 may worsen alopecia areata instead of helping it.
Search
for
Sort by
Research
480-510 / 1000+ results
research Prevalence of skin lesions in a sample of Brazilian patients with inflammatory bowel disease
Brazilian patients with inflammatory bowel disease have a high rate of skin problems compared to healthy people.
research Acne and hidradenitis suppurativa
Acne and hidradenitis suppurativa have different causes and risk factors, but both are driven by inflammation and may benefit from treatments targeting interleukin-1.
research Alopecia secondary to severe discoid lupus responding to anifrolumab
Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.
research How the Innate Lymphoid Cells Improved Our Understanding of the Mechanisms of Allergic Diseases and Influenced the Standpoint?
Innate lymphoid cells help us understand and manage allergic diseases better.
research Ruxolitinib Rescues Multiorgan Clinical Autoimmunity in Patients with APS-1
Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
research [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
research The role of B cell-activating factor system in autoimmune diseases: mechanisms, disease implications, and therapeutic advances
BAFF-targeted therapies can reduce autoimmune disease activity, but more research is needed for precise treatments.
research Development of Alopecia Areata Universalis in a Patient Receiving Adalimumab
Adalimumab may cause severe hair loss in some patients.
research A clinical study of pemphigus vulgaris and its variants, evaluation of safety and efficacy of glucocorticoids versus immunosuppressants at tertiary care hospital: a study of 75 cases
Combining glucocorticoids with immunosuppressants like cyclophosphamide improves remission and reduces relapse in pemphigus patients.
research Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus
Baricitinib might help treat hair loss in lupus patients, but more research is needed.
research Infliximab as First‐Line Therapy in Severe Pediatric Crohn Disease
Early use of infliximab in severe pediatric Crohn's disease can lead to significant improvement and remission.
research New treatments for rheumatoid arthritis
New drugs for rheumatoid arthritis show improvement but have side effects and are not a cure.
research POS0080 TOFACITINIB TREATMENT IN CHILDREN WITH RHEUMATIC DISEASES: SINGLE-CENTER EXPERIENCE
Tofacitinib is a promising treatment for children with rheumatic diseases.
research VITILIGO: WHAT’S OLD, WHAT’S NEW?
Vitiligo treatments are improving but relapses are common.
research Multiomic Characterization of Treatment Response to JAK Inhibition in Patients with APECED
Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.
research Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment
Infections during JAK inhibitor treatment for alopecia areata are usually manageable and rarely stop treatment permanently.
research Common Pediatric Skin Conditions with Protracted Courses
Some new treatments for children's skin conditions are effective, but risks must be weighed.
research Leflunomide: an unlikely trigger and mechanistically a beneficial drug for alopecia areata
Leflunomide is more likely to help treat alopecia areata than cause it.
research Mixed Connective Tissue Disease (MCTD) in a Girl with Lower Extremities Edema: A Brief Report
MCTD should be considered in children with recurring muscle issues, lupus-like symptoms, and edema.
research 521 Deciphering Pathomechanisms in Solar Urticaria
The study found that skin inflammation and immune response pathways are activated in Solar Urticaria patients after UV exposure, unlike in healthy people.
research The development of universal alopecia during therapy with TNF-α inhibitors in patients with ankylosing spondylitis: description of three cases
TNF-α inhibitors may cause complete hair loss in some patients with ankylosing spondylitis.
research Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and Contact Immunotherapy in the Treatment of severe alopecia areata: a systematic review and network meta-analysis
Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
research Successful Treatment of Coexisting Alopecia Areata and Bullous Pemphigoid With Dupilumab: A Case Report
Dupilumab successfully treated a woman's alopecia areata and bullous pemphigoid, leading to full hair regrowth and symptom resolution.
research Alopecia Areata
Understanding the immune-related causes of Alopecia Areata has led to potential treatments like JAK inhibitors.
research Autoimmunity: Alopecia Areata
Alopecia areata is an autoimmune disease causing hair loss, treatable with immune-modulating drugs, and linked to genetics.
research Treatment outcomes and considerations for topical immunotherapy in patients with alopecia totalis and alopecia universalis
Topical immunotherapy can help with severe hair loss, but results vary and need personalized, long-term treatment.
research JAK1 gain-of-function variant causes alopecia areata, atopic dermatitis, and autoimmune thyroid disease
A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.
research Successful hair regrowth in an acute diffuse form of alopecia areata during oral tacrolimus treatment in a patient with rheumatoid arthritis
Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.
research Overlapping features of atopic dermatitis and alopecia areata: from pathogenesis to treatment
Atopic dermatitis and alopecia areata share immune and genetic factors, and targeted therapies may help both.